{"id":"69d3b330-4676-467d-846b-bc919fe3fb57","kind":"institutions","code":"UB-I5386","name":"Huiruizhiyao","nameBasis":"transliterated","summary":"Huiruizhiyao is a Chinese corporate strategic investment entity, investing industrial capital in growth-stage and mature companies.","description":"Huiruizhiyao is a Chinese corporate strategic investment entity, investing industrial capital in growth-stage and mature companies.","country":null,"category":null,"originalName":"辉瑞制药","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T12:04:29.534Z","englishUpdatedAt":"2026-10-15T18:43:03.653Z","reviewedAt":"2026-10-15T18:43:03.653Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"19d44125e90f4bdb356673c54854b5a6682643e7c06a0dc6965d465857d2bb5e","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"辉瑞制药，中国企业开展战略投资的投资主体，以产业资本布局成长期与成熟期企业。","sources":[],"related":[{"id":"d537c012-b7aa-4228-969b-b31e8ef7c43d","kind":"news","code":"d537c012-b7aa-4228-969b-b31e8ef7c43d","name":"cytoReason raises USD 80 million in strategic financing","nameBasis":"translated-title","summary":"","description":"","country":null,"category":null,"originalName":"cytoReason完成8000万美元战略投资融资","eventDate":"2024-07-18T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-14T11:38:13.219Z","englishUpdatedAt":"2026-10-15T17:20:00.058Z","reviewedAt":"2026-10-15T17:20:00.058Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"5eab5a1aa9aa0ec81ef053a5c3c43a64a2261db7adec1d7b0f6ccb91c732b2ac","companyId":"5d107c78-a2e8-409e-9b53-5aa8d34c431a","foundedYear":null,"logoUrl":null,"path":"/news/d537c012-b7aa-4228-969b-b31e8ef7c43d"}],"path":"/institutions/huiruizhiyao","displayName":"辉瑞制药","displayNameLang":"zh","structured":{"city":null,"country":"China (mainland)","location":null,"role":null,"category":null,"company":null},"definition":"辉瑞制药 is a strategic investor based in China (mainland) with 1 recorded investment.","summaryBasis":"translated","thin":false,"canonical":"https://uniquebase.ai/institutions/huiruizhiyao"}